Inventor · disambiguated record
Jean-Marie Cuillerot
Also filed as: CUILLEROT JEAN-MARIE
8 granted patents·7 pending applications·31 citations·filing 2016–2025
84Inventor score
Top patents by PatentIndex Score
15 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0296US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0396US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0493US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 0585US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 0684US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 0781US12377144B2Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·1 cites·20 claims
- 0875US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 0960US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1056US2023416402A1Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1156US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1249US2023272041A1Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused ProteinsDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1348US2020362040A1Pd-1/pd-l1 inhibitors for the treatment of cancerMERCK PATENT GMBH·Filed 2020·Application pending·0 cites
- 1447US10800846B2PD-1/PD-L1 inhibitors for the treatment of cancerMERCK PATENT GMBH·Filed 2016·Granted Oct 13, 2020·0 cites·9 claims
- 1544US2021221894A1Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tamsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jean-Marie Cuillerot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →